Krystal Biotech (KRYS) Cash from Investing Activities Growth (1y) (2017 - 2026)
Krystal Biotech (KRYS) Cash from Investing Activities Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Krystal Biotech | 10.38 Bn | 9.56 Bn | 110.08 Mn | -16.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.09% |
| Dec 31, 2025 | 113.32% |
| Sep 30, 2025 | 87.51% |
| Jun 30, 2025 | 45.62% |
| Mar 31, 2025 | -110.81% |
| Dec 31, 2024 | -724.59% |
| Sep 30, 2024 | -132.63% |
| Jun 30, 2024 | -21.28% |
| Mar 31, 2024 | -829.16% |
| Dec 31, 2023 | -95.08% |
| Sep 30, 2023 | 813.50% |
| Jun 30, 2023 | 58.25% |
| Mar 31, 2023 | 106.37% |
| Dec 31, 2022 | 95.88% |
| Sep 30, 2022 | 60.33% |
| Jun 30, 2022 | 38.66% |
| Mar 31, 2022 | -7,384.34% |
| Dec 31, 2021 | -1,935.39% |
| Sep 30, 2021 | -1,278.05% |
| Jun 30, 2021 | -6,377.86% |